Objective: The aim of this study was to evaluate recent trends and the adoption of practice recommendations for menopausal hormone therapy (MHT) use from 2001 to 2009 by formulation, dose, woman's age, and characteristics of physicians reporting MHT visits. Methods: The IMS Health (Plymouth Meeting PA) National Disease and Therapeutic Index physician survey data from 2001 to 2009 were analyzed for visits in which MHT use was reported by US office-based physicians. Estimated national volume of visits for which MHT use was reported. Results: MHT use declined each year since 2002. Systemic MHT use fell from 16.3 million (M) visits in 2001 to 6.1 M visits in 2009. Declines were greatest for women 60 years or older (64%) but were also substantial for women younger than 50 years (59%) and women 50 to 59 years old (60%). Women 60 years or older accounted for 37% of MHT use. Lower dose product use increased modestly, from 0.7 M (2001) to 1.3 M (2009), as did vaginal MHT use, from 1.8 M (2001) to 2.4 M (2009). Declines in continuing systemic MHT use (65%) were greater than for newly initiated MHT use (51%). Compared with other physicians, obstetrician/gynecologists changed their practices less, thereby increasing their overall share of total MHT visits from 72% (2001) to 82% (2009).
T he large randomized, placebo-controlled Women's Health Initiative (WHI) estrogen plus progestin (E + P) trial in postmenopausal women was stopped in July 2002 because the cardiovascular and breast cancer risks of combined conjugated equine estrogens (CEE) and medroxyprogesterone outweighed the health benefits. 1 Menopausal hormone therapy (MHT) use, particularly CEE plus medroxyprogesterone use, decreased dramatically after this report. 2 Clinical guidance from the US Food and Drug Administration (FDA) and other groups emphasized that MHT should not be used for prevention but was still appropriate, at the lowest effective dose and for the shortest duration, for managing moderate to severe menopausal symptoms. 3, 4 However, accumulating evidence beginning with the 2004 WHI CEE-only trial in women with prior hysterectomy showed a more balanced risk-benefit profile 5 and suggested a possible cardiovascular benefit in women aged 50 to 59 years 6 or closer to menopause. [7] [8] [9] This led to consensus statements 10, 11 stating that MHT initiated in women younger than 60 years does not increase coronary heart disease risk and possibly decreases it. Conversely, other research showed no cardiovascular benefit in younger women 12 and has reinforced and extended evidence on MHT-associated harms, particularly for breast cancer [13] [14] [15] [16] and cognitive function. 17 Thus, we sought to determine whether national MHT use continues to decline in the context of this new evidence, the current clinical recommendations, and recent consensus statements. We assessed changes in product type and dose, continuing or newly initiated use, woman's age, and physician specialty using nationally representative data.
METHODS

Data source
Data were extracted from the January 2000 through December 2009 National Disease and Therapeutic Index (NDTI) that provides nationally representative estimates on practices of nonfederally employed US office-based physicians via a physician survey conducted by IMS Health (Plymouth Meeting, PA). 18 The survey uses a two-stage stratified cluster design: physicians are sampled in the first stage, with visits of each physician sampled at the second stage. Physicians providing direct patient care are selected from the master lists of all US physicians compiled by the American Medical Association and the American Osteopathic Association (both of Chicago, IL) via a random, stratified sample by geographic region and specialty (designed to match national patterns). Physicians may participate in the survey continuously and are replaced when they discontinue participation. Each calendar quarter, approximately 1,800 participating physicians report on all patients evaluated on two consecutive and randomly assigned workdays. In 2009, the survey included 340,820 projected patient encounters as office visits (89%), hospital visits (7%), telephone calls (2%), and other contacts (2%).
For each patient encounter, physicians report all patient diagnoses and all medications prescribed to treat each unique diagnosis. 19 Medications include those available over the counter. Physicians note whether a medication is newly prescribed or is continued from a previous visit, and each medication is recorded as a Bdrug use.[ An individual patient encounter may generate more than one drug use if the same drug is used to treat more than one diagnosis. For 8% of uses, newly initiated versus continuing medication status was not available, and these were categorized as continuing medications in this analysis. Detailed patient demographics, including age, sex, ethnicity, and insurance coverage, are recorded. Physician characteristics included age, sex, and specialty. NTDI survey questions include for each unique diagnosis (1) a description of the diagnosis or reason for visit, (2) for this diagnosis only, a record of all prescriptions, over-the-counter products, and vitamins exactly as issued or recommended for this diagnosis, and (3) for each product, information on whether it was previously ordered and continued or started this visit. For much of our analysis, we aggregated information across all diagnoses that prompted MHT use.
Information collected from NDTI visits is projected to national estimates accounting for physician nonresponse and geographic patterns of physician practice. The 95% CIs for these estimates were calculated from relative standard error formulas that varied with sample size. 20 The NDTI database has several advantages over alternative databases of outpatient visits. NDTI provides more current information compared with federal survey data and private and governmental health insurance data. NDTI also provides nationally representative data with large sample sizes. Larger samples are available only for data that are regionally and demographically distinct, whereas national coverage is available only from less current federal surveys. The NDTI database has also been cross-validated against other national sources of information on outpatient practice. 21, 22 
Measures
Using NDTI 2001 to 2009 annual data, we selected patient visits by women older than 18 years where MHT was mentioned. Annual survey responses meeting this definition decreased from 4,163 in 2001 to 1,936 in 2009. Figure 1 includes year 2000 data to highlight the relative stability in MHT use before 2002.
The primary outcome measure was the estimated national volume of visits for which MHT use was reported by office-based physicians. Trends in reported MHT use were differentiated by estrogen formulation, including route of administration, the presence of other hormones, and estrogen dose. MHT was categorized as systemic (defined as oral, transdermal, and intramuscular) or vaginal. MHT was categorized as estrogen therapy alone (ET) or with a progestogen or androgen (EPT), noting that the estrogen and androgen combination was infrequently reported. EPT can be reported as either a combination product or separate products at the same visit. Standard estrogen doses were equivalent to CEE doses of 0.625 mg or greater. Lower doses were CEE 0.3 and 0.45 mg and micronized estradiol 0.5 mg. We grouped women as younger than 50 years, 50 to 59 years of age, or 60 years or older and differentiated obstetrician/gynecologists (Ob/Gyns) from other physicians who were mostly in primary care. The magnitude of the decline in standarddose oral ET increased with advancing age (ie, 62% in those aged G50 y, 71% in those aged 50-59 y, and 77% in those Q60 y), whereas standard-dose oral EPT use decreased more in younger and older women (88% in those G50 y and 83% in those Q60 y vs 81% in those aged 50-59 y; Fig. 2) . 
RESULTS
2001-2009 MHT use
MHT use by other patient characteristics
In 2001, MHT visits comprised 5% (14 M; 95% CI, 12.7-15.3) of a total 284 M physician visits by women 40 to 70 years old, of which 80% were for whites (5% of which were for MHT use) and 20% were for nonwhites (of which 4% were for MHT use). In 2009, MHT visits comprised 2.8% (7M; 95% CI, 6.2-7.8) of a total 246 M physician visits, of which 76% were for whites (3% for MHT use) and 24% were for nonwhites (2% for MHT use). For all patient visits associated with MHT, the proportion of MHT visits for whites and blacks was similar in 2001 (83.4% and 8.1%, respectively) and 2009 (83.3% and 6.9%, respectively; Table 1 ). Most MHT visits were associated with private insurance in both 2001 (70%) and 2009 (70.9%), with a small portion having no insurance coverage both years (2% and 2%, respectively).
MHT use by physician characteristics
Ob/Gyns were associated with a larger proportion of 2001 MHT visits (72%) compared with primary care physicians and physicians in other specialties (28%; Table 2 ). Smaller 2001 to 2009 declines in Ob/Gyn MHT visits (46%) compared with those in other-specialty visits (69%) increased Ob/Gyns' proportion to 82% in 2009. For both Ob/Gyn and other specialties, MHT patient visits were more likely to be associated with male, not female, physicians (Table 2 ). However, by 2009, this gap was smaller, more so for specialties other than Ob/Gyn. Ob/Gyn MHT visits were more often associated with older physicians (Q55 y), whereas other-specialty MHT visits were more often associated with younger physicians (45-54 y), particularly in 2001. The specialty differential in decreasing MHT use was observed for all categories for which MHT use continued to decline from 2004 to 2009 (28% decline), but at a slower rate than during the years immediately after the 2002 publication of the WHI E + P trial results (47%). Overall, 2009 systemic MHT use was 37% of its 2001 level. MHT doses and route of administration also changed, with lower dose oral MHT use increasing from 0.7 M (2001) to 1.3 M (2009), transdermal MHT use remaining stable from 1.5 M to 1.5 M, vaginal MHT use increasing from 1.8 M to 2.4 M, and oral EPT use declining slightly more (76%) than ET use (62%). Women 60 years or older reduced systemic MHT use more (64%) than younger women did (60%), yet continued to account for a sizable portion of MHT use (31% of systemic MHT in 2009, down from 32% in 2001). Few prescription (eg, antidepressants) or nonprescription (eg, dietary supplements) alternatives to MHT were used for menopause-related diagnoses.
DISCUSSION
Nationally representative data on MHT use among patients visiting US outpatient physicians indicate that systemic MHT
These findings extend previously reported trends in US and international studies 2,23-27 and indicate no resurgence in MHT use through 2009. Declining MHT use largely reflects changes initiated after the publication of WHI E + P trial results, including physicians' increased awareness of the net benefits versus the risks of MHT use. In addition, new evidence, along with clinical guidelines, continues to help inform physicians and women about MHT use. For example, the WHI CEE-only trial 5 and others [14] [15] [16] 28 found a temporal association of reduced breast cancer incidence with reduced MHT use, whereas other studies have assessed differential risk by age or years since menopause. 7, 29, 30 Current guidelines and FDA recommendations support MHT starting at the lowest effective dose for the shortest duration of time necessary for treatment of significant menopausal symptoms. 3, 10, 31, 32 Despite the successful translation of clinical trial results into practice, further modification of MHT prescribing practices may be needed, particularly with respect to distinctions based on MHT dose, route of administration, coadministration of progestogens, and women's age.
Lower dose MHT
Accumulating evidence suggests that lower dose MHT is effective for vasomotor symptoms and osteoporosis prevention and may have a better safety profile than does MHT in standard doses. 10, [33] [34] [35] [36] In observational studies, lower dose MHT does not seem to raise cardiovascular risk in young, healthy, symptomatic women. 34, 37 We observed, however, that standard-dose oral MHT use continues to exceed lower dose oral MHT use. Although use of lower dose formulations increased after the 2003 introduction of Premarin Low (CEE 0.45 mg) and Prempro Low (CEE 0.3 and 0.45 mg), their use decreased after 2005. Despite new lower dose MHT options in various routes of administration, we did not observe prominent use of these products. Current recommendations 3, 10, 31, 32 to use the lowest dose MHT effective for symptom relief should receive greater consideration.
Transdermal MHT
Transdermal MHT, which foregoes first-pass hepatic metabolism, is hypothesized to reduce cardiovascular and venous thromboembolic risk compared with oral MHT because of reduced stimulation of liver proteins and a more favorable metabolic profile. 38 Given the value of transdermal MHT in controlling vasomotor symptoms, 39, 40 it is surprising that transdermal MHT use has not increased overall from 2001 to 2009.
Vaginal formulations
The North American Menopause Society recommends that vaginal MHT be used only when vulvovaginal symptoms are present and that lower dose oral estrogen be used for women with persistent vulvovaginal symptoms, 32 consistent with 2003 FDA recommendations. 3 We report only modestly increased vaginal MHT use from 2001 to 2009, suggesting possible underutilization of this therapy despite increased availability of lower dose products.
EPT versus ET
In the WHI hormone trials, the health risks of EPT exceeded the benefits, whereas a neutral risk-to-benefit ratio was found for ET alone. 1, 5 It may be that some harms associated with EPT derive from progestogens. 41 Our data indicate that absolute declines in EPT use continue to exceed those for ET from 2001 to 2009. Greater differentiation between ET and EPT use in older age groups may especially be warranted, as a lower threshold for MHT may be appropriate for younger, symptomatic posthysterectomy women with vasomotor symptoms.
Use in younger women
Cardiovascular disease prevalence is generally low in younger women, and lower dose oral MHT or nonoral routes of administration may be effective and safer for managing symptoms in perimenopausal women. 5, 7, 42 Thus, it seems appropriate that systemic MHT use decreased less in younger women than in those 60 years or older. Younger symptomatic women provided with low-dose, limited-duration MHT may face a limited increase in the absolute risk of adverse events.
Physicians are important disseminators of current evidence and guidelines. Risk-benefit discussions should be undertaken in any woman contemplating MHT. Although most critical among women at a higher risk of complications because of increased age or the presence of specific comorbidities, such discussions should take place also in younger women who are considering MHT for moderate to severe vasomotor symptoms. In the absence of such symptoms, MHT is not recommended because potential risks may outweigh benefits.
Use in older women
Concerns about MHT use in older women have increased since 2002 with new evidence of cardiovascular and cancer risks that highlight hazards in older women. 7, 13, 29, 43 The temporal association of a population-wide decline in breast cancer incidence and decreases in MHT use reinforce cautions regarding MHT use in women at moderate to high risk of breast cancer, which may include the substantial number of older women receiving MHT. Although lack of past MHT-related adverse events in older women is stated as justification for continuing MHT, this does not equate to a lack of future risk.
Limitations
Several limitations deserve attention. NDTI includes physicians in nonfederal office-based private practices and excludes those in publicly funded practices, who are more likely to serve lower income patients. Physicians may vary in how they classify new versus continued MHT use. In particular, reinitiation of prior MHT may not be coded consistently. NDTI patient visits may not represent the general population of women and their patterns of MHT use. In particular, women seeking MHT-specific care and those making more physician visits are probably overrepresented. NDTI lacks patient interview information that might have added greater depth to the observed practice patterns, particularly for the limited uptake of low-dose and topical products. Given our data's lack of detailed information on patient symptoms and response to past therapies, there are inherent limitations in commenting on the appropriateness of current practice patterns.
CONCLUSIONS
Current guidelines stress tailoring MHT decisions to an individual's risks and benefits. Although the continued decline in and transformation of MHT have shifted in the direction of available evidence and guidelines, further refinements in practice may be warranted. Despite reduced use, standard-dose oral MHT remains the dominant formulation, yet lower dose oral formulations, as well as transdermal and vaginal preparations may yield less harm. The potentially lower risk of ET may suggest a lower threshold for its use compared with EPT. Older women are at increased risk for CVD events and breast cancer, risks that are more likely to outweigh the benefits of systemic MHT. In healthy younger women, however, the benefits of MHT for treatment of moderate to severe symptoms may compensate for disease risks. Future researchers should seek to provide more detailed risk-benefit information on both subpopulations and different forms of MHT. At present, greater recognition of distinctions based on MHT dose, route of administration, need for concomitant progestogens, and woman's age may move clinical practice into better alignment with currently available evidence.
